Best Practice & Research Clinical Obstetrics & Gynaecology
Volume 25, Issue 6 , Pages 681-689 , December 2011

Clinical presentation and diagnosis of uterine sarcoma, including imaging

  • Tzu-I. Wu, MD (Assistant Professor)

      Affiliations

    • Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan
    • ,
  • Tzu-Chen Yen, MD, PhD (Professor and Chairperson)

      Affiliations

    • Department of Nuclear Medicine, Chang Gung Memorial Hospital, Linkou Medical Center, 5 Fu-Shin Street, Kueishan, Taoyuan 333, Taiwan
    • ,
  • Chyong-Huey Lai, MD (Professor and Director)

      Affiliations

    • Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan
    • Corresponding Author InformationCorresponding author. Tel.: +886 3 3281200; Fax: +886 3 3288252.

References 

  1. Curtin JP, Kavanagh JJ, Fox H, et al. Corpus: mesenchymal tumors. In:  Hoskins WJ,  Perex CA,  Young RC editor. Principles and practice of gynecologic oncology. Philadelphia (PA): Lippincott Williams and Wilkins; 2002;p. 919
  2. Harlow BL, Weiss NS, Lofton S. The epidemiology of sarcomas of the uterus. J Natl Cancer Inst. 1986;76:399–402
  3. Amant F, Coosemans A, Debiec-Rychter M, et al. Clinical management of uterine sarcomas. Lancet Oncol. 2009;10:1188–1198
  4. FIGO committe on gynecologic oncology. FIGO staging for uterine sarcomas. Int J Gynecol Cancer. 2009;104:179
  5. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Uterine neoplasms V.1.2010; http://www.nccn.org/professionals/physician_gls/PDF/uterine.pdf (last accessed 25 June 2011).
  6. Silverberg SG, Major FJ, Blessing JA, et al. Carcinosarcoma (MMMT) of the uterus: a GOG pathologic study of 203 cases. Int J Gynecol Pathol. 1990;9:1–9
  7. Major FJ, Blessing JA, Silverberg SG, et al. Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer. 1993;71:1702S–1709S
  8. Yamada DS, Burger RA, Brewster WR, et al. Prognostic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus. Cancer. 2000;88:2782–2786
  9. Livi L, Paiar F, Shah N, et al. Uterine sarcoma: twenty-seven years of experience. Int J Radiat Oncol Biol Phys. 2003;57:1366–1373
  10. Nordal RN, Kj?rstad KE, Stenwig AE, et al. Leiomyosarcoma (LMS) and endometrial stromal sarcoma (ESS) of the uterus. A survey of patients treated in the Norwegian Radium Hospital 1976–1985. Int J Gynecol Cancer. 1993;3:110–115
  11. Echt G, Jepson J, Steel J, et al. Treatment of uterine sarcomas. Cancer. 1990;66:35–39
  12. Dinh TA, Oliva EA, Fuller AF, et al. The treatment of uterine leiomyosarcoma. Results form a 10-year experience (1990–1999) at the Massachusetts General Hospital. Gynecol Oncol. 2004;92:648–652
  13. Brooks SE, Zhan M, Cote T, et al. Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989–1999. Gynecol Oncol. 2004;93:204–208
  14. Thomas MB, Keeney GL, Podratz KC, et al. Endometrial stromal sarcoma: treatment and patterns of recurrence. Int J Gynecol Cancer. 2009;19:253–256
  15. Chan JK, Kawar NM, Shin JY, et al. Endometrial stromal sarcoma: a population-based analysis. Br J Cancer. 2008;99:1210–1215
  16. Alcazar JL, Galvan R. Three-dimensional power Doppler ultrasound scanning for the prediction of endometrial cancer in women with postmenopausal bleeding and thickened endometrium. Am J Obstet Gynecol. 2009;200:e44.e1–e44.e6
  17. Sahdev A, Sohaib SA, Jacobs I, et al. MR imaging of uterine sarcomas. Am J Roentgenol. 2001;177:1307–1311
  18. Tanaka YO, Nishida M, Tsunoda H, Okamoto Y, Yoshikawa H. Smooth muscle tumors of uncertain malignant potential and leiomyosarcomas of the uterus. MR findings. J Magn Reson Imaging. 2004;20:998–1007
  19. Ho KC, Lai CH, Wu TI, et al. 18F-fluorodeoxyglucose positron tomography in uterine carcinosarcoma. Eur J Nucl Med Mol Imaging. 2008;35:484–492
  20. Livasy CA, Reading FC, Moore DT, et al. EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma. Gynecol Oncol. 2006;100:101–106
  21. McCluggage WG. Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas?. J Clin Pathol. 2002;55:321–325
  22. Galaal K, Kew FM, Tam KF, et al. Evaluation of prognostic factors and treatment outcomes in uterine carcinosacoma. Eur J Obstet Gynecol Reprod Biol. 2009;143:88–92
  23. Wu TI, Hsu KH, Huang HJ, et al. Prognostic factors and adjuvant therapy in uterine carcinosarcoma. Eur J Gynaecol Oncol. 2008;29:483–487
  24. Nemani D, Mitra N, Guo M, et al. Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma: A SEER analysis. Gynecol Oncol. 2008;111:82–88
  25. Iwasa Y, Haga H, Konishi I, et al. Prognostic factors in uterine carcinosarcoma: a clinicopathologic study of 25 patients. Cancer. 1998;82:512–519
  26. Sartori E, Bazzurini L, Gadducci A, et al. Carcinosarcoma of the uterus: a clinicopathological multicenter CTF study. Gynecol Oncol. 1997;67:70–75
  27. Amant F, Cadron I, Fuso L, et al. Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk endothelial endometrial cancer. Gynecol Oncol. 2005;98:274–280
  28. Zaloudek C, Hendrickson MR. Mesenchymal tumors of the uterus. In:  Kurman RJ editors. Blaustein’s pathology of the female genital tract. New York: Springer-Verlag, Inc.; 2002;p. 578–583
  29. Kapp DS, Shin JY, Chan JK. Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas. Emphasis on impact of lymphadenectomy and oophorectomy. Gynecol Oncol. 2008;111:82–88
  30. Parker WH, Fu YS, Berek JS. Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma. Obstet Gynecol. 1994;83:414–418
  31. Hsieh CH, Lin H, Huang CC, et al. Leiomyosarcoma of the uterus: a clinicopathologic study of 21 cases. Acta Obstet Gynecol Scand. 2003;82:74–81
  32. Blom R, Guerrieri C, Stal O, et al. Leiomyosarcoma of the uterus: a clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 49 cases. Gynecol Oncol. 1998;68:54–61
  33. Hoffmann W, Schmandt S, Kortmann RD, et al. Radiotherapy in the treatment of uterine sarcomas: A retrospective analysis of 54 cases. Gynecol Obstet Invest. 1996;42:49–57
  34. Mayerhofer K, Obermair A, Windbichler G, et al. Leiomyosarcoma of the uterus: A clinicopathologic multicenter study of 71 cases. Gynecol Oncol. 1999;74:196–201
  35. Hannigan EV, Gomez JD. Leiomyosarcoma of the uterus. Am J Gynecol. 1979;134:557–564
  36. Peters WA, Howard DR, Anderson WA, et al. Uterine smooth-muscle tumors of uncertain malignant potential. Obstet Gynecol. 1994;83:1015–1020
  37. Raut CP, Nucci MR, Wang Q, et al. Predictive value of FIGO and AJCC staging systems in patients with uterine leiomyosarcoma. Eur J Cancer. 2009;45:2818–2824
  38. World Health Organization classification of tumours. In:  Tavassoli FA,  Devilee P editor. Pathology and genetics of tumours of the breast and female genital organs. Lyon: IARC Press; 2003;
  39. D’Angelo E, Prat J. Uterine sarcomas: a review. Gynecol Oncol. 2010;116:131–139
  40. McMeekin DS. Sarcoma of the uterus. In:  DiSaia PJ,  Creasman WT editor. Clinical gynecologic oncology. 5th ed.. China: Mosby Elsevier; 2007;p. 185–199
  41. Timor-Tritsch IE, Monteagudo A. Three and four-dimentional ultrasound in obstetrics and gynecology. Curr Opin Obstet Gynecol. 2007;19:157–175
  42. Raine-Fenning NJ, Campbell BK, Clewes JS, et al. The reliability of virtual organ computer-aided analysis (VOCAL) for the semiquantification of ovarian, endometriual and subendometrial perfusion. Ultrasound Obstet Gynecol. 2003;22:633–639
  43. Mercé LT, Alcázar JL, Engels V, et al. Endometrial volume and vascularity measurements by transvaginal three-dimensional ultrasonography and power Doppler angiography in stimulated and tumoral endometria: intraobserver reproducibility. Gynecol Oncol. 2006;100:544–550
  44. Alcázar JL, Mercé LT, Manero MG, et al. Endometrial volume and vascularity measurements by transvaginal 3-dimensional ultrasonography and power Doppler angiography in stimulated and tumoral endometria: an interobserver reproducibility. J Ultrasound Med. 2005;24:1091–1098
  45. Foster FS, Bunrs PN, Simpson DH, et al. Ultrasound for the visualization and quantification of tumor microcirculation. Cancer Metastasis Rev. 2000;19:131–138
  46. Goertz DE, Yu JL, Kerbel RS, et al. High-frequency 3-D color-flow imaging of the microcirculation. Ultrasound Med Biol. 2003;29:39–51
  47. Ueda M, Otsuka M, Hatakenaka M, Torii Y. Uterine endometrial stromal sarcoma located in uterine myometrium: MRI appearance. Eur Radiol. 2000;10:780–782
  48. Le Bihan D, Breton E, Lallemand D, et al. MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders. Radiology. 1986;161:401–407
  49. Schaefer PW, Grant PE, Gonzalez RG. Diffusion-weighted MR imaging of the brain. Radiology. 2000;217:331–345
  50. Thoeny HC, De Keyzer F. Extracranial applications of diffusion-weighted magnetic resonance imaging. Eur Radiol. 2007;17:1385–1393
  51. Tamai K, Koyama T, Saga T, et al. The utility of diffusion-weighted MR imaging for differentiating uterine sarcomas from benign leiomyomas. Eur Radiol. 2008;18:723–730
  52. Namimoto T, Yamashita Y, Awai K, et al. Combined use of T2-weighted and diffusion-weighted 3-T MR imaging for differentiating uterine sarcomas from benign leiomyomas. Eur Radiol. 2009;19:2756–2764
  53. Rigo P, Paulus P, Kaschten B, et al. Oncological applications positron emission tomography with fluorin-18 fluorodeoxyglucose. Eur J Nucl Med. 1996;23:1641–1674
  54. Umesaki N, Tanaka T, Miyama M, et al. Positron emission tomograophy with 18F-Fluorodeoxyglucose of uterine sarcomas: A comparison with magnetiac resonance imaging and power Doppler imaging. Gynecol Oncol. 2001;80:372–377
  55. Park JY, Kim EN, Kim DY, et al. Role of PET or PET/CT in the post-therapy surveillance of uterine sarcoma. Gynecol Oncol. 2009;109:255–262
  56. Murakami M, Tsukada H, Shida M, et al. Whole-body positron emission tomography with F-18 fluorodeoxyglucose for the detection for recurrence in uterine sarcomas. Int J Gynecol Cancer. 2006;16:854–860
  57. Punta SEW, Earya JF, O’Sullivanb J, et al. Role of PET or PET/CT in the post-therapy surveillance of uterine sarcoma. Nucl Med Commun. 2009;30:546–549

PII: S1521-6934(11)00106-4

doi: 10.1016/j.bpobgyn.2011.07.002

Best Practice & Research Clinical Obstetrics & Gynaecology
Volume 25, Issue 6 , Pages 681-689 , December 2011

Article Tools

* Image Usage & Resolution